Clinical Trial Update: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GS-248 for safety and efficacy in Raynaud's phenomenon associated with systemic sclerosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• GS-248 (GS-248)

Snippet

Sponsor: Gesynta Pharma AB | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2024-08-09